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Introduction: BODE index comprises Body mass index, Obstruction of the airway [FEV1], Dys-
pnoea score [modified Medical Research Council questionnaire] and Exercise capacity [6 min
walk test]. This study assessed the role of serial changes in BODE index in predicting mortality
and readmissions of COPD patients.
Methods: A prospective cohort study involving 243(208males) COPD patients hospitalized for
acute exacerbations of COPD [AECOPD]. BODE index was assessed at 6 weeks(baseline), 6,
12, 18 and 24 months post hospital discharge. Mortality and readmissions in the subsequent
3 years were recorded. All the patients were managed by usual care without additional inter-
vention.
Results: Themean (SD) age and FEV1% predictedwere 74.2(7.8) yrs and 51.7(21.6)% respectively.
Over the 3 years, 25.1% diedwhereas 76.5% had at least 1 readmission for AECOPD. Baseline BODE
index was predictive of both the survival and readmissions to hospital for AECOPD by Cox regres-
sion analysis (p < 0.001 for both survival and readmissions). Over 24 months, 71(40.1%), 94
(53.1%), 12(6.8%) patients had increased (>1point), no change, and decreased in BODE (>1point)
index respectively. Serial changes in BODE index at 6 month was marginally associated with
mortality, but not at 12-, 18- and 24-month. The 6-, 12- and 24-month BODE indices were predic-
tive of the readmissions for AECOPD when compared to baseline.t; AECOPD, acute exacerbations of COPD; COPD, chronic obstructive pulmonary disease; FEV1, forced
ital capacity; ICS, inhaled steroid; LABA, long acting beta-agonist; mMRC, modified Medical Research
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Variable
FEV1 (% of predicted)
Distance walked in 6 min (m)
mMRC dyspnoea scale
Body Mass Index (kg/m2)
mMRC Z Modified Medical ResearchConclusion: Baseline BODE index could predict both survival and readmissions for AECOPD,
whereas serial BODE indices were not predictive of survival at 3 years. Single rather than serial
measurements of BODE index is sufficient for prediction of survival and readmissions for patients
treated with usual care.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
COPD is a common disease worldwide with a high burden on
healthcare resources.1,2 The prevalence of COPD varied
from 11.4 to 26.1% according to a recent multi-city pop-
ulation study using spirometry.1 In Hong Kong, the preva-
lence rates of COPD in the elderly population aged 60
years were 25.9% and 12.4% based on the spirometric
definition of forced expiratory volume in 1 s (FEV1)/forced
vital capacity (FVC) ratio <70% and the lower limit of
normal of the FEV1/FVC respectively.
3 In 2005, the crude
mortality rate of COPD was 29.1/100,000, while the crude
hospitalization rate was 193/100,000 in Hong Kong.4
In Hong Kong, COPD ranked second as a respiratory cause
for hospitalization and inpatient bed-days. In those 75 years
or older, the hospitalization rate for COPD was as high as
2225/100,000.4 The economic burden of COPD on the
society is enormous.5,6
The BODE index, a simple multidimensional grading
system, was developed in 2004 by Celli and colleagues, for
predicting mortality risk of COPD patients. The BODE index
included the body mass index (B), degree of airflow
obstruction (O) measured by FEV1, dyspnea (D) measured
by a simple dyspnea questionnaire,7 and exercise capacity
(E) measured by the 6-minewalk test.8 Studies have shown
that BODE index could predict mortality better in COPD
patients than FEV1 alone.
8,9 Subsequent studies also
demonstrated that BODE index could predict hospital
admissions for COPD.10,11
All except one previous study on BODE index focused
on the index at one time point and its predictive power on
mortality, exacerbations and hospital readmissions of
COPD.8,10,12 The only study that involved serial BODE
indices on mortality assessed patients who were treated
with either lung volume reduction surgery or best medical
care.13 There are currently no data on the ability of serial
changes in BODE indices for predicting the mortality and
readmissions for COPD patients in those who were treated
with usual care (real life treatment, not necessarily the
best medical treatment according to guidelines14,15). This
study assessed the role of serial BODE indices inE index. The total possible valu
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Council.predicting the mortality and hospitalizations of COPD
subjects who were treated with usual care over a 3 year
period.
Material and methods
This was a prospective study of patients who had been
admitted to the Prince of Wales Hospital with acute exac-
erbations of COPD (AECOPD) between May 1, 2004, and
April 30, 2005. AECOPD was defined as occurring when
a patient with background COPD,14 with FEV1/FVC ratio
<70%, presented with at least two major symptoms
(increased dyspnea, increased sputum purulence, or
increased sputum volume), or one major and one minor
symptom (nasal discharge/congestion, wheeze, sore
throat, or cough) for at least 2 consecutive days.16e19
Written informed consent was obtained from each
subject, and the study was approved by the Ethics
Committee of the Chinese University of Hong Kong.
Upon discharge from hospital, subjects attended the
pulmonary function laboratory for assessment at 6e8 weeks
(baseline), 6 months, 12 months, 18 months, and
24 months. BODE index was measured at each visit and
hospital admissions were recorded. At the baseline assess-
ment, the demographic characteristics and the medication
usage of the subjects were recorded. Co-morbid conditions
were scored using the Charlson index20 which ranged from
0 to 33, with a higher score indicating more in the number
and severity of the coexisting illnesses.
Telephone follow-up to check for any hospital admis-
sions or death was arranged for subjects who did not return
for assessment. At the end of the 3 years, patients were
contacted by phone to assess for readmissions and
mortality. Hospital records were also reviewed at the end
of the study. Any readmissions and the cause of death
would be recorded. These subjects were treated with usual
care with no specific intervention. No pulmonary rehabili-
tation was offered except for those subjects who could not
be discharged directly. These subjects would be transferred
to convalescent hospital for a short course (usually for
a week) of inpatient pulmonary rehabilitation.es range from 0 to 10.
ex
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Figure 1 Distribution of the BODE index of the subjects at baseline (n Z 243).
Table 2 Demographic characteristics of the subjects (n Z 243).
Age (years) 74.22  7.80
Sex Male 208(85.6%)
Female 35(14.4%)
Smoking status Current smoker 61(25.1%)
Ex-smoker 181(74.5%)
Non-smoker 1(0.4%)
Premorbid status Chair bound 2(0.8%)
Home bound 12(4.9%)
Could walk on level ground 50(20.6%)
Could walk up at least one flight of stairs 179(73.7%)
BMI (kg/m2) 21.41  4.70
FEV1 (L)
b 0.87  0.38
FEV1% predicted
b 51.70  21.59
FEV1/FVC ratio
b 57.58  14.85
mMRC dyspnoea score 1.8  0.9
6 min walk test (m)a 262.3  99.0
No. of hospitalizations
in the previous 12 months
1.17  1.63
Home oxygen use 21/243 (8.6%)
Home NPPV use 2/243 (0.8%)
Medications use ICS 108/243 (44.4%)
LABA 5/243(2.06%)
Long acting anti-cholinergic 1/243 (0.41%)
Theophylline 79/242 (32.6%)
Influenza vaccination in the
past 12 months
83/243 (34.2%)
Comorbidities Charlson index 1.45  0.82
Diabetes mellitus 29/243 (11.9%)
Hypertension 76/243 (31.3%)
Ischaemic Heart disease 20/243 (8.2%)
Cerebrovascular disease 8/243 (3.3%)
Data are presented in mean  SD or n (%).
BMI: body mass index.
MMRC: modified Medical Research Council.
NPPV: non-invasive positive pressure ventilation.
a n Z 243.
b post-bronchodilator measurements.
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Figure 2 KaplaneMeier survival curves for the four quartiles of the BODE index and survival.
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Weight and height were measured to compute the Body
Mass Index, Obstruction of the airway was assessed by
spirometry before and after bronchodilator therapy
(20 min after inhaling 400 mg of salbultamol through
a 500 mL spacer [Ventolin; GlaxoSmithKline, Evreux,
France]) according to the American Thoracic Society
standard21 using a spirometer (Vitalograph; Bucking-
ham, UK). The updated predicted spirometry values for
Hong Kong Chinese were adopted.22 The degree ofFigure 3 KaplaneMeier survival curves of the baseline BODE
index and first readmissions for AECOPD.Dyspnoea was measured by the modified Medical
Research Council (mMRC) questionnaire with a score
ranging from 0e4.7 Exercise capacity was measured by
6-min walk test (6-MWT).23 The BODE index, an 11
point composite score (0 through 10) was then
computed as shown in Table 1 according to Celli et al.8
Satistics
Data were analyzed using a statistical software package
(SPSS for Windows, version 13.0; SPSS Inc; Chicago, IL).
Data for continuous variables were presented as means
[SD]. Cox proportional hazards regression analyses were
used to assess the capacity of BODE index to predict the
risk of mortality.24 The predictive characteristics of the
baseline BODE index for survival and first readmission for
AECOPD were assessed by KaplaneMeier analysis accord-
ing to quartiles of the BODE index and the statistical
significance was evaluated by the log-rank test. The
predictive characteristics of the changes in serial BODE
indices for survival and first readmission of AECOPD were
assessed by KaplaneMeier analysis (serial change at
a certain time point was classified as having decreasing
[>1point], stable or increasing [>þ1point] BODE indices
based on their absolute change from baseline) and
statistical significance was evaluated with the use of the
log-rank test. The index of concordance was used to
directly compare the predictive ability of the baseline
BODE index and its separate components on mortality and
first readmission for AECOPD.
Figure 4 KaplaneMeier survival curves showing the changes in BODE index over time and survival. Group 1: BODE index
decreased by >1 point; Group 2: Stable BODE index; Group 3:BODE index increased by >1 point.
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Altogether 327 subjects were recruited for this study. As 20
subjects could not perform satisfactory spirometry whereas
64 subjects were unable to perform 6-MWT (either too
breathless to walk, having arthritis or old cerebrovascular
accident that limited their mobility) at the baseline study,
we have only included 243 subjects for our analysis. The
mean [SD] age was 74.2[7.8] yrs with moderate airflow
obstruction (post-bronchodilator FEV1% predicted was 51.7
[21.6]%). The majority of the subjects were current
smokers (25.1%) or ex-smokers (74.5%) with smoking history
of 52.3[23.6] and 44.0[25.6] pack years respectively.
A significant number (69.5%[169/243]) of patients had
co-morbidity (11.9%, 31.3%, 8.2% and 3.3% with diabetes
mellitus, hypertension, ischaemic heart disease and old
cerebrovascular accident respectively) and about half of
them were on inhaled corticosteroid with an average dose
of 1329.1[604.5] mcg of beclomethasone dipropionate
equivalent per day. The mean (SD) BODE index at baseline
was 4.30 (2.25) and its distribution is shown in Fig. 1. With
usual care, the mean (SD) 6, 12, 18 and 24 month BODE
indices were 4.4(2.5), 4.7(2.6), 5.1(2.5) and 5.2(2.6)
respectively. Using a 1-point difference as the cut-off,
40.1%, 53.1% and 6.8% of the patients had increased
(>1point), no change (change in 1 point), and decreased
in BODE (>1point) index over 24 months respectively. Using
a 2 point difference, 19.8%, 78.5%, 1.7% patients hadincreased (>2 points), no change (change in 2 points), and
decreased in BODE index (>2 points) over 24 months
respectively. The mean values and changes of BODE index
over time are shown in Table 2.
Over the 3 years, 25.1%(61/243) had died. There was no
difference in the mortality between the current smokers
and ex-smokers (24.9% [45/181] vs 26.2% [16/61], pZ 0.83)
Among the deceased, 29.5%(18/61), 6.6%(4/61), 13.1%(8/
61) died of COPD, pneumonia, and lung cancer respectively.
The non-pulmonary causes of death included 6 malignan-
cies (1 esophagus, 1 stomach, 2 large bowel, 1 chol-
angiocarcinoma, 1 hepatocellular carcinoma), 2 acute
myocardial infarction, 2 biliary sepsis, 1 cerebrovascular
accident, 1 gastrointestinal bleeding, 1 intestinal obstruc-
tion, 1 perforation of colon, 1 acute renal failure, 15
sudden death and 1 suicide. Subjects had on average (SD)
3.37(3.80) admissions (range 0e25) over 3 years whereas
76.5%(186/243) had at least 1 readmission for AECOPD.
Patients with higher baseline BODE scores were at higher
risk for death and readmission; the hazard ratios for death
and readmissions from any cause per one-point increase in
the baseline BODE score were 1.25 (95% CI, 1.12e1.39;
P < 0.001) and 1.12(95% CI, 1.05e1.20; P < 0.001)
respectively. When stratifying the baseline BODE index into
4 quartiles (first quartile with a BODE index of 0e2, second
quartile 3e4, third quartile 5e6, fourth quartile 7e10),8
there were significant differences in the mortality rates
among the quartiles (p < 0.001), with a higher BODE score
Figure 5 KaplaneMeier survival curves showing the changes in BODE index over time and readmissions for COPD. Group 1: BODE
index decreased by >1 point; Group 2: Stable BODE index; Group 3:BODE index increased by >1 point.
Serial BODE index in COPD patients 271showing a higher mortality over time. Similar pattern was
observed for the relationship between baseline BODE index
and first hospital readmissions for AECOPD with earlier
readmissions among those with higher BODE scores. Base-
line BODE index also correlated weakly with the number of
readmissions over 3 years (r Z 0.301, p < 0.001). The
KaplaneMeier Curves for both the mortality and first
readmissions and the four quartiles of the baseline BODE
index are shown in Figs. 2 and 3.
Serial change of BODE index (>þ1 point, static or >1
point) was marginally predictive of mortality when the 6th
month BODE index was compared with the baseline BODE
index. However, the serial change of BODE index was notTable 3 BODE index of our subjects at different time points.
Time Point Baseline
n 243
BODE index 4.30  2.25
Change in BODE indexa Increased >1 point
No change
Decreased >1 point
With missing BODE index (excluding death), n 0
Subjects died, n
Data are presented in mean  SD or n (%).
a compared with baseline line.predictive of the mortality when the 12th, 18th and 24th
months BODE indices were compared with the baseline line
BODE index (Fig. 4). The 6th, 12th and 24th month BODE
indices when compared to the baseline BODE index
however showed that patients with increased BODE index
of >1 point had earlier readmissions to hospital than those
with static or decreasing BODE index (Fig. 5). The 18th
month BODE index when compared with the baseline BODE
index were not predictive of readmissions for AECOPD.
The concordance indices of the baseline BODE index in
predicting survival and readmissionsat36monthsare shown in
Table 4. The index of concordance allows us to quantify the
predictive ability of a survival model. Baseline BODE index6 month 12 month 18 month 24 month
220 199 181 177
4.44  2.54 4.71  2.61 5.14  2.55 5.20  2.61
42 (19.1%) 55 (27.7%) 67 (37.0%) 71(40.1%)
151(68.6%) 129 (64.8%) 101 (55.8%) 94 (53.1%)
27(12.3%) 15 (7.5%) 13 (7.2%) 12 (6.8%)
7 9 18 20
16 35 44 46
Table 4 The concordance indices of the baseline BODE
index in predicting survival and first readmissions over 3
years (n Z 307).
Baseline variables Survival First
readmission
BODE index 0.68 0.58
Post-bronchodilator FEV1
(% predicted)
0.64 0.60
6 min walk distance (m) 0.66 0.54
BMI (kg/m2) 0.65 0.56
mMRC score 0.66 0.57
BMI Z body mass index; mMRC Z modified Medical Research
Council.
272 F.W.S. Ko et al.could predict the survival of the COPD patients better than
post-bronchodilator FEV1% predicted, BMI, 6-MWT and MMRC
score alone. However, for prediction of the first readmissions
for AECOPD, post-bronchodilator FEV1% predicted alone
appeared to do better than the BODE index at baseline.
Discussion
This study has shown that with usual care and no additional
intervention, baseline BODE index could predict both the
mortality and readmissions for AECOPD in our group of
COPD patients who had a high rate of mortality and
morbidity. For those subjects with a baseline BODE index in
the 4th quartile (BODE index score of 7e10), half of the
subjects died in 3 years. By 3 years, almost 80% of the
subjects had at least 1 readmission for AECOPD. The serial
changes of BODE index of the surviving patients, however,
did not show any relationship with survival but appeared to
have some predictive effect on readmissions. Similar to
previous studies, the baseline BODE index predicted
mortality more accurately than FEV1 alone.
8
In a study that had assessed serial changes in BODE index
over time by comparing one group of COPD patients being
treated with lung volume reduction surgery against another
group that was treated with maximal medical therapy,
Martinez et al have shown that an increase in the modified
BODE index was associated with increased mortality in both
groups of subjects, particularly in the medical treatment
group.13 In addition, a decrease in modified BODE of more
than 1 point was predictive of lower mortality in the entire
cohort and, particularly, the surgically treated cohort.13
This study however did not address the relationship
between the change in serial BODE index and readmissions
for AECOPD.13 Subjects in our current study were different
from those in Martinez et al’s study as none of our patients
had received lung volume reduction surgery and our
patients were just treated with usual medical care. The
majority of the patients in our study did not receive long
acting beta-agonist (LABA), long acting anti-cholinergic
therapy or a combination of inhaled steroid (ICS) and LABA
therapy (See Table 2). Our patients also did not receive
proper pulmonary rehabilitation programme. In the “real”
world, a lot of COPD patients were not treated according to
the guidelines due to limited healthcare budget.25 It is
interesting that under usual care, patients did not havemuch change in their BODE index over a 3 year period in our
study (the mean levels were similar over the different time
points [Table 3]). This might be the reason why the baseline
BODE index could predict mortality whereas serial BODE
indices could not.
To the best of our knowledge, this is the first study to
assess the role of BODE index among Chinese COPD patients
and we found that, similar to the western population,
a cross-sectional BODE index could predict overall mortality
and the hospital readmission for COPD over a period of
3 years. Interestingly, the hazard ratio for change of 1 point
of the baseline BODE index in relationship to the mortality
in this current study was similar to the study by Celli et al.8
It appears that the BODE index is applicable to both the
Caucasians and Chinese COPD subjects using the same cut-
off values for calculation.
AECOPD leads to significant morbidity and mortality
worldwide.14 Previous studies16,26 have shown that pulmo-
nary function and quality of life were adversely affected by
frequent exacerbations, particularly in active smokers.
Studies have shown that a number of factors including
infection,18,19,27e29 outdoor air pollution,30,31 withdrawal
of medications32 and changes in temperature33 were asso-
ciated with AECOPD. This study concurs with previous
studies10,34 that the baseline BODE index of COPD patients
is capable of predicting COPD-related hospitalization.10,11
The mechanisms underlying AECOPD are poorly under-
stood, and it is important to identify factors that help
predicting their occurrences.35 It is likely that the changes
in serial BODE indices of the patients would interact with
the above mentioned factors (such as infectious agents,
changes in level of pollutants, temperature and drug
regime), and together with the presence of co-morbidity,
could increase the likelihood of developing AECOPD and its
related hospitalizations. This could possibility explain why
serial BODE indices alone, without taking all these factors
into account, could not reliably predict admissions for
AECOPD in our study. Studies to assess the interactions of
serial BODE indices with the above mentioned factors would
be interesting and potentially useful for better under-
standing of mechanisms of AECOPD.
This study was limited by the fact that this was a single
center study and our subjects were in general “sicker” as
they were recruited after recovery from an episode of
AECOPD that required hospitalization. However, it is
important to understand the natural history and the
predictor of morbidity and mortality of this group of
subjects as they were the main group of COPD subjects that
accounted for most of the burden of COPD on the health-
care utilization. When assessing the morbidity of the
subjects, we only captured the hospitalization episodes,
but not the emergency room visits and primary care visits.
It is unlikely that the mortality and hospitalization data
were subjected to recall bias as we had obtained the
information not only from the subjects, but cross checked
with the hospital records.
In conclusion, a single measurement of BODE index could
predict mortality and readmissions of COPD patients over
time. Serial measurements of the BODE index six monthly
for 2 years were not useful for predicting mortality but
appeared to have some predictive effect on readmissions in
a group of patients treated with usual care.
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